Long-term Safety and Antitumor Activity in the Phase 1–2 Study of Enzalutamide in Pre- and Post-docetaxel Castration-Resistant Prostate Cancer

BACKGROUND: Given that some patients with castration-resistant prostate cancer (CRPC) have shown extended responses to the androgen receptor inhibitor enzalutamide, long-term safety of this drug is of interest. OBJECTIVE: To evaluate the long-term safety and antitumor activity of enzalutamide in CRP...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Eur Urol
Autors principals: Higano, Celestia S., Beer, Tomasz M., Taplin, Mary-Ellen, Efstathiou, Eleni, Hirmand, Mohammad, Forer, David, Scher, Howard I.
Format: Artigo
Idioma:Inglês
Publicat: 2015
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5013546/
https://ncbi.nlm.nih.gov/pubmed/25698064
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.eururo.2015.01.026
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars